Aspartate metabolism in endothelial cells activates the mTORC1 pathway to initiate translation during angiogenesis.
Animals
Aspartic Acid
/ metabolism
Cell Line
Endothelial Cells
/ metabolism
Humans
Mechanistic Target of Rapamycin Complex 1
/ metabolism
Mice
Neovascularization, Pathologic
/ metabolism
Neovascularization, Physiologic
/ physiology
Protein Biosynthesis
/ physiology
Pyrimidines
Receptors, Vascular Endothelial Growth Factor
/ metabolism
Signal Transduction
Vascular Endothelial Growth Factor A
/ metabolism
Vascular Endothelial Growth Factor Receptor-2
/ metabolism
angiogenesis
aspartate metabolism
endothelial metabolism
mTOR signalling
tumor angiogenesis
Journal
Developmental cell
ISSN: 1878-1551
Titre abrégé: Dev Cell
Pays: United States
ID NLM: 101120028
Informations de publication
Date de publication:
23 05 2022
23 05 2022
Historique:
received:
22
09
2021
revised:
24
02
2022
accepted:
25
04
2022
pubmed:
18
5
2022
medline:
27
5
2022
entrez:
17
5
2022
Statut:
ppublish
Résumé
Angiogenesis, the active formation of new blood vessels from pre-existing ones, is a complex and demanding biological process that plays an important role in physiological as well as pathological settings. Recent evidence supports cell metabolism as a critical regulator of angiogenesis. However, whether and how cell metabolism regulates endothelial growth factor receptor levels and nucleotide synthesis remains elusive. We here shown in both human cell lines and mouse models that during developmental and pathological angiogenesis, endothelial cells (ECs) use glutaminolysis-derived glutamate to produce aspartate (Asp) via aspartate aminotransferase (AST/GOT). Asp leads to mTORC1 activation which, in turn, regulates endothelial translation machinery for VEGFR2 and FGFR1 synthesis. Asp-dependent mTORC1 pathway activation also regulates de novo pyrimidine synthesis in angiogenic ECs. These findings identify glutaminolysis-derived Asp as a regulator of mTORC1-dependent endothelial translation and pyrimidine synthesis. Our studies may help overcome anti-VEGF therapy resistance by targeting endothelial growth factor receptor translation.
Identifiants
pubmed: 35580611
pii: S1534-5807(22)00286-6
doi: 10.1016/j.devcel.2022.04.018
pii:
doi:
Substances chimiques
Pyrimidines
0
Vascular Endothelial Growth Factor A
0
Aspartic Acid
30KYC7MIAI
Receptors, Vascular Endothelial Growth Factor
EC 2.7.10.1
Vascular Endothelial Growth Factor Receptor-2
EC 2.7.10.1
Mechanistic Target of Rapamycin Complex 1
EC 2.7.11.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1241-1256.e8Subventions
Organisme : Cancer Research UK
ID : C596/A17196
Pays : United Kingdom
Informations de copyright
Copyright © 2022 Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests The authors declare no competing interests.